Cargando…

Eldecalcitol reduces the risk of severe vertebral fractures and improves the health-related quality of life in patients with osteoporosis

Eldecalcitol reduces the risk of vertebral fractures in comparison to alfacalcidol in osteoporotic patients under vitamin D repletion. The aim of this study was to evaluate the effects of eldecalcitol on the spinal location of incident vertebral fractures, the severity of the fractures, and the chan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hagino, Hiroshi, Takano, Toshiyuki, Fukunaga, Masao, Shiraki, Masataka, Nakamura, Toshitaka, Matsumoto, Toshio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Japan 2012
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3590407/ https://www.ncbi.nlm.nih.gov/pubmed/23129180 http://dx.doi.org/10.1007/s00774-012-0397-6

Ejemplares similares

Eldecalcitol is more effective for the prevention of osteoporotic fractures than alfacalcidol
por: Nakamura, Toshitaka, et al.
Publicado: (2013)

Three years of treatment with minodronate in patients with postmenopausal osteoporosis
por: Hagino, Hiroshi, et al.
Publicado: (2011)

Effect of Bone Resorption Inhibitors on Serum Cholesterol Level and Fracture Risk in Osteoporosis: Randomized Comparative Study Between Minodronic Acid and Raloxifene
por: Ohta, Hiroaki, et al.
Publicado: (2023)

Eldecalcitol for the treatment of osteoporosis
por: Noguchi, Yuko, et al.
Publicado: (2013)

Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study
por: Matsumoto, T., et al.
Publicado: (2008)

24-Month Open-Label Teriparatide Once-Weekly Efficacy Research Trial Examining Bone Mineral Density in Subjects with Primary Osteoporosis and High Fracture Risk
por: Sugimoto, Toshitsugu, et al.
Publicado: (2017)

Once-Weekly Injection of Low-Dose Teriparatide (28.2 μg) Reduced the Risk of Vertebral Fracture in Patients with Primary Osteoporosis
por: Fujita, Takuo, et al.
Publicado: (2013)

Japanese 2011 guidelines for prevention and treatment of osteoporosis—executive summary
por: Orimo, Hajime, et al.
Publicado: (2012)

Clinical Trials Express: Fracture Risk Reduction With Denosumab in Japanese Postmenopausal Women and Men With Osteoporosis: Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT)
por: Nakamura, Toshitaka, et al.
Publicado: (2014)

Effects of eldecalcitol on cortical bone response to mechanical loading in rats
por: Yamasaki, Yusuke, et al.
Publicado: (2015)

Overview of the clinical efficacy and safety of eldecalcitol for the treatment of osteoporosis
por: Cui, Lijia, et al.
Publicado: (2022)

Additive effects of eldecalcitol in poorly responding long-term bisphosphonate treatment for osteoporosis
por: Kamimura, Mikio, et al.
Publicado: (2019)

Safety and Efficacy of Zoledronic Acid Treatment with and without Acetaminophen and Eldecalcitol for Osteoporosis
por: Mochizuki, Takeshi, et al.
Publicado: (2021)

Efficacy and safety of monthly oral minodronate in patients with involutional osteoporosis
por: Okazaki, R., et al.
Publicado: (2011)

Human hepatic metabolism of the anti-osteoporosis drug eldecalcitol involves sterol C4-methyl oxidase
por: Yasuda, Kaori, et al.
Publicado: (2015)

Efficacy and Safety of Eldecalcitol for Osteoporosis: A Meta-Analysis of Randomized Controlled Trials
por: Liu, Hongyan, et al.
Publicado: (2022)

Association of Urinary Pentosidine Levels With the Risk of Fractures in Patients With Severe Osteoporosis: The Japanese Osteoporosis Intervention Trial‐05 (JOINT‐05)
por: Tanaka, Shiro, et al.
Publicado: (2022)

Effects of monthly minodronate with or without eldecalcitol addition in osteoporosis patients with rheumatoid arthritis: An 18-month prospective study
por: Suzuki, Takako, et al.
Publicado: (2019)

Effects of eldecalcitol and ibandronate on secondary osteoporosis and muscle wasting in rats with adjuvant-induced arthritis
por: Ono, Yuichi, et al.
Publicado: (2018)

Eldecalcitol, an active vitamin D analog, effectively prevents cyclophosphamide-induced osteoporosis in rats
por: Wang, Wei, et al.
Publicado: (2019)

Increased Bone Mineral Density with Monthly Intravenous Ibandronate Contributes to Fracture Risk Reduction in Patients with Primary Osteoporosis: Three-Year Analysis of the MOVER Study
por: Hagino, Hiroshi, et al.
Publicado: (2014)

The therapeutic effect to eldecalcitol + bisphosphonate is superior to bisphosphonate alone in the treatment of osteoporosis: a meta-analysis
por: Zheng, Zaoqian, et al.
Publicado: (2020)

Comparison of effectiveness and safety of ibandronate and minodronate combined with eldecalcitol in primary osteoporosis of women: A 1-year follow-up study
por: Tanaka, Mizue, et al.
Publicado: (2017)

Comparison of the Effects of Native Vitamin D and Eldecalcitol on Muscular Strength and Dynamic Balance in Patients with Postmenopausal Osteoporosis
por: Miyakoshi, Naohisa, et al.
Publicado: (2020)

Correction to: The therapeutic effect to eldecalcitol + bisphosphonate is superior to bisphosphonate alone in the treatment of osteoporosis: a meta-analysis
por: Zheng, Zaoqian, et al.
Publicado: (2020)

The Synergistic Effect of Zuogui Pill and Eldecalcitol on Improving Bone Mass and Osteogenesis in Type 2 Diabetic Osteoporosis
por: Shi, Tuo, et al.
Publicado: (2023)

Eldecalcitol is more effective in promoting osteogenesis than alfacalcidol in Cyp27b1-knockout mice
por: Hirota, Yoshihisa, et al.
Publicado: (2018)

Clinical Efficacy on Fracture Risk and Safety of 0.5 mg or 1 mg/month Intravenous Ibandronate Versus 2.5 mg/day Oral Risedronate in Patients with Primary Osteoporosis
por: Nakamura, Toshitaka, et al.
Publicado: (2013)

Implications of historical height loss for prevalent vertebral fracture, spinal osteoarthritis, and gastroesophageal reflux disease
por: Nakano, Masaki, et al.
Publicado: (2020)

Two-year effectiveness of zoledronic acid with or without eldecalcitol in Japanese patients with osteoporosis: A randomized prospective study
por: Mochizuki, Takeshi, et al.
Publicado: (2022)

Efficacy and safety of once-yearly zoledronic acid in Japanese patients with primary osteoporosis: two-year results from a randomized placebo-controlled double-blind study (ZOledroNate treatment in Efficacy to osteoporosis; ZONE study)
por: Nakamura, T., et al.
Publicado: (2016)

Study of twice-weekly injections of Teriparatide by comparing efficacy with once-weekly injections in osteoporosis patients: the TWICE study
por: Sugimoto, T., et al.
Publicado: (2019)

Strontium ranelate reduces the risk of vertebral fracture in young postmenopausal women with severe osteoporosis
por: Roux, C, et al.
Publicado: (2008)

Vertebroplasty in osteoporosis-related vertebral fractures
por: Sadat-Ali, Mir
Publicado: (2008)

Pentosidine and carboxymethyl-lysine associate differently with prevalent osteoporotic vertebral fracture and various bone markers
por: Nakano, Masaki, et al.
Publicado: (2020)

Eldecalcitol prevented OVX-induced osteoporosis through inhibiting BMSCs senescence by regulating the SIRT1-Nrf2 signal
por: Kou, Yuying, et al.
Publicado: (2023)

Comparative effect of eldecalcitol and alfacalcidol on bone microstructure: A preliminary report of secondary analysis of a prospective trial
por: Ni, Xiaolin, et al.
Publicado: (2021)

Sequential therapy with once-weekly teriparatide injection followed by alendronate versus monotherapy with alendronate alone in patients at high risk of osteoporotic fracture: final results of the Japanese Osteoporosis Intervention Trial-05
por: Mori, Satoshi, et al.
Publicado: (2022)

Acute Phase Reactions After Intravenous Infusion of Zoledronic Acid in Japanese Patients with Osteoporosis: Sub-analyses of the Phase III ZONE Study
por: Shiraki, Masataka, et al.
Publicado: (2021)

Treatment of osteoporosis with eldecalcitol, a new vitamin D analog: a comprehensive review and meta-analysis of randomized clinical trials
por: Xu, Zhixing, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_95f4u61rn5ak9qkp5eg92uel4p